The Sanofi Patient ConnectionTM (SPC) provider portal allows you to enroll and manage your patients in the suite of access services. The secure web-based portal is available 24 hours a day, 7 days a week.

Reimbursement Connection: one-stop resource for insurance issues

Red Blood Cell 1

Online or over the phone, counselors are available to assist with the following:

  • Benefit verification: Verification of benefits specific to Mozobil and the patient’s plan
  • Preauthorization assistance: Identification of plan-specific requirements with counselors to help navigate the process
  • Coding and billing support: Assistance for program products and their respective regimens
  • Claims management and appeals assistance: Help with appeals should a denial be received

How to request support through SPC

Online resources available 24/7:

Informational website for patients and providers:

Provider portal for healthcare professionals:

1.888.VISITSPC (1.888.847.4877)
Available M–F, 9 am–8 pm EST

Patient Assistance Connection: no cost medication for eligible patients

This component of the program is made possible through the Sanofi Foundation for North America. Eligibility requirements include*:

  • Patient must be a U.S. citizen or resident and be under the care of the licensed healthcare provider authorized to prescribe, dispense, and administer medicine in the U.S.
  • Patient must have no insurance coverage or not have access to the prescribed product or treatment via their insurance
  • Patient must not be eligible for Medicare or Medicaid
    • See program application for Medicare Part D eligibility criteria*
  • Patient must meet the following financial criteria:
    • Annual household income of ≤250% of the current Federal Poverty Level for all non-oncology/non-hematology products
    • Annual household income of ≤500% of the current Federal Poverty Level for all oncology and hematology products

Sanofi Patient Connection Application. 40KB

*See program application for a complete list of eligibility criteria and application directions

To assess current Federal Poverty Level details, visit

Red Blood Cell 1

Resource Connection: additional resources and support

  • Clinical Support Services
  • Nutritional Supplements (groceries, food banks, etc)
  • Transportation
  • Health Supply/Cosmetic Aids (wigs, scarves, etc)
  • Patient Advocacy Support
  • Home Care Services Support (shelter, utilities, etc)

Dosing and Administration

Learn about the process of administering Mozobil.

access dosing schedule

About Mozobil

In clinical trials, Mozobil + granulocyte-colony stimulating factor (G-CSF) was shown to significantly reduce mobilization failures. Learn more about the clinical trials.1-3

see study results


  1. Mozobil [prescribing information]. Cambridge, MA: Genzyme Corporation; 2017.
  2. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(28):4767-4773.
  3. DiPersio JF, Stadtmauer EA, Nademanee A, et al; for the 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726.